Celgene to buy Pharmion
- Share via
NEW YORK — Drug maker Celgene Corp. has agreed to acquire Pharmion Corp. for $72 a share in a cash-and-stock deal valued at $2.9 billion, the companies said Sunday.
Summit, N.J.-based Celgene said the deal would further its strategy in the hematology/oncology field and would bring together three therapies -- Revlimid, Thalomid and Vidaza -- that are expected to accelerate revenue and earnings growth over the next five years.
Under the deal, each share of Boulder, Colo.-based Pharmion would be exchanged for $25 in cash and Celgene shares to be determined by an exchange ratio. Upon closing, Pharmion stockholders will own 6% of Celgene’s outstanding shares.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
